Used in pharmaceutical synthesis as a protected intermediate for developing active pharmaceutical ingredients (APIs), particularly in the production of kinase inhibitors and central nervous system agents. The Boc-protected amine group allows selective reactivity, while the methylaminomethyl functionality serves as a key linker for further derivatization. Commonly employed in solid-phase and solution-phase peptide-like synthesis where controlled deprotection and coupling are required. Its structural rigidity supports conformational optimization in drug candidates targeting neurological disorders and inflammatory conditions.